{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:08:48Z","timestamp":1792667328188,"version":"4.5.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T00:00:00Z","timestamp":1737849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T00:00:00Z","timestamp":1737849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP170079"],"award-info":[{"award-number":["RP170079"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP180712"],"award-info":[{"award-number":["RP180712"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP180712"],"award-info":[{"award-number":["RP180712"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP170079"],"award-info":[{"award-number":["RP170079"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP180712"],"award-info":[{"award-number":["RP180712"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA255960"],"award-info":[{"award-number":["CA255960"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA223772"],"award-info":[{"award-number":["CA223772"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Breast Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Endocrine therapy with CDK4\/6 inhibitors is standard for estrogen receptor-positive, HER2\u2212negative metastatic breast cancer (ER+\/HER2\u2212 MBC), yet clinical resistance develops. Previously, we demonstrated that low doses of palbociclib activate autophagy, reversing initial G1 cell cycle arrest, while high concentrations induce off-target senescence. The autophagy inhibitor hydroxychloroquine (HCQ) induced on-target senescence at lower palbociclib doses. We conducted a phase I trial (NCT03774472 registered in ClinicalTrials.gov on 8\/20\/2018) of HCQ (400, 600, 800\u2009mg\/day) with palbociclib (75\u2009mg\/day continuous) and letrozole, using a 3\u2009+\u20093 design. Primary objectives included safety, tolerability, and determining the recommended phase 2 dose (RP2D) of HCQ. Secondary objectives included tumor response and biomarker analysis. Fourteen ER+\/HER2\u2212 MBC patients were evaluable [400\u2009mg (<jats:italic>n<\/jats:italic>\u2009=\u20094), 600\u2009mg (<jats:italic>n<\/jats:italic>\u2009=\u20094), 800\u2009mg (<jats:italic>n<\/jats:italic>\u2009=\u20096)]. Grade 3 adverse events (AEs) included hematological (3 at 800\u2009mg), skin rash (2 at 600\u2009mg), and anorexia (1 at 400\u2009mg), with no serious AEs. The best responses were partial (2), stable (11), and progression (1). Tumor reductions ranged from 11% to 30%, with one 55% increase. The two partial responders sustained tumor size reductions of 30% to 55% over an extended treatment period, lasting nearly 300 days. Biomarker analysis in responders demonstrated significant decreases in Ki67, Rb, and nuclear cyclin E levels and increases in autophagy markers p62 and LAMP1, suggesting a correlation between these biomarkers and treatment response. This phase I study demonstrated that HCQ is safe and well-tolerated and the RP2D was established at 800\u2009mg\/day with continuous low-dose palbociclib (75\u2009mg\/day) and letrozole (2.5\u2009mg\/day). These findings suggest that adding HCQ could potentially enhance the efficacy of low-dose palbociclib and standard letrozole therapy, pending verification in larger randomized studies.<\/jats:p>","DOI":"10.1038\/s41523-025-00722-1","type":"journal-article","created":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T10:31:19Z","timestamp":1737887479000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Phase I trial of hydroxychloroquine to enhance palbociclib and letrozole efficacy in ER+\/HER2\u2212 breast cancer"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6425-4400","authenticated-orcid":false,"given":"Akshara Singareeka","family":"Raghavendra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2043-4407","authenticated-orcid":false,"given":"Nicole M.","family":"Kettner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Kwiatkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senthil","family":"Damodaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9566-8975","authenticated-orcid":false,"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan S.","family":"Gombos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9156-8723","authenticated-orcid":false,"given":"Kelly K.","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3899-7868","authenticated-orcid":false,"given":"Yu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5440-0849","authenticated-orcid":false,"given":"Khandan","family":"Keyomarsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5711-2404","authenticated-orcid":false,"given":"Debu","family":"Tripathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,26]]},"reference":[{"key":"722_CR1","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1158\/1055-9965.EPI-16-0520","volume":"26","author":"AM Noone","year":"2017","unstructured":"Noone, A. M. et al. Cancer incidence and survival trends by subtype using data from the surveillance epidemiology and end results program, 1992-2013. Cancer Epidemiol. Biomark. Prev. 26, 632\u2013641 (2017).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"722_CR2","doi-asserted-by":"crossref","unstructured":"Howlader, N. et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J. Natl. Cancer Inst. 106, dju055 (2014)","DOI":"10.1093\/jnci\/dju055"},{"key":"722_CR3","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1158\/1055-9965.EPI-16-0889","volume":"26","author":"AB Mariotto","year":"2017","unstructured":"Mariotto, A. B., Etzioni, R., Hurlbert, M., Penberthy, L. & Mayer, M. Estimation of the number of women living with metastatic breast cancer in the United States. Cancer Epidemiol. Biomark. Prev. 26, 809\u2013815 (2017).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"722_CR4","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ejca.2020.01.016","volume":"129","author":"E Deluche","year":"2020","unstructured":"Deluche, E. et al. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008\u20132016. Eur. J. cancer 129, 60\u201370 (2020).","journal-title":"Eur. J. cancer"},{"key":"722_CR5","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s10549-018-05125-4","volume":"174","author":"H Rugo","year":"2019","unstructured":"Rugo, H. et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res. Treat. 174, 719\u2013729 (2019).","journal-title":"Breast Cancer Res. Treat."},{"key":"722_CR6","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","volume":"29","author":"GN Hortobagyi","year":"2018","unstructured":"Hortobagyi, G. N. et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2\u2212negative advanced breast cancer. Ann. Oncol. 29, 1541\u20131547 (2018).","journal-title":"Ann. Oncol."},{"key":"722_CR7","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz, M. P. et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J. Clin. Oncol. 35, 3638\u20133646 (2017).","journal-title":"J. Clin. Oncol."},{"key":"722_CR8","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.annonc.2020.12.013","volume":"32","author":"M Martin","year":"2021","unstructured":"Martin, M. et al. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial\u2014PEARL. Ann. Oncol. 32, 488\u2013499 (2021).","journal-title":"Ann. Oncol."},{"key":"722_CR9","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1093\/annonc\/mdy192","volume":"29","author":"F Cardoso","year":"2018","unstructured":"Cardoso, F. et al. 4th ESO\u2013ESMO international consensus guidelines for advanced breast cancer (ABC 4). Ann. Oncol. 29, 1634\u20131657 (2018).","journal-title":"Ann. Oncol."},{"key":"722_CR10","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","volume":"31","author":"F Cardoso","year":"2020","unstructured":"Cardoso, F. et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann. Oncol. 31, 1623\u20131649 (2020).","journal-title":"Ann. Oncol."},{"key":"722_CR11","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"M Cristofanilli","year":"2016","unstructured":"Cristofanilli, M. et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2\u2212negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 17, 425\u2013439 (2016).","journal-title":"Lancet Oncol."},{"key":"722_CR12","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","volume":"19","author":"D Tripathy","year":"2018","unstructured":"Tripathy, D. et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 19, 904\u2013915 (2018).","journal-title":"Lancet Oncol."},{"key":"722_CR13","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.ccell.2021.03.010","volume":"39","author":"JM Suski","year":"2021","unstructured":"Suski, J. M., Braun, M., Strmiska, V. & Sicinski, P. Targeting cell-cycle machinery in cancer. Cancer Cell 39, 759\u2013778 (2021).","journal-title":"Cancer Cell"},{"key":"722_CR14","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nrclinonc.2016.26","volume":"13","author":"B O\u2019Leary","year":"2016","unstructured":"O\u2019Leary, B., Finn, R. S. & Turner, N. C. Treating cancer with selective CDK4\/6 inhibitors. Nat. Rev. Clin. Oncol. 13, 417\u2013430 (2016).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"722_CR15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","volume":"16","author":"RS Finn","year":"2015","unstructured":"Finn, R. S. et al. The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2\u2212negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study. Lancet Oncol. 16, 25\u201335 (2015).","journal-title":"Lancet Oncol."},{"key":"722_CR16","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn, R. S. et al. Palbociclib and letrozole in advanced breast cancer. N. Engl. J. Med. 375, 1925\u20131936 (2016).","journal-title":"N. Engl. J. Med."},{"key":"722_CR17","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","volume":"375","author":"GN Hortobagyi","year":"2016","unstructured":"Hortobagyi, G. N. et al. Ribociclib as first-line therapy for hr-positive, advanced breast cancer. N. Engl. J. Med. 375, 1738\u20131748 (2016).","journal-title":"N. Engl. J. Med."},{"key":"722_CR18","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","volume":"36","author":"DJ Slamon","year":"2018","unstructured":"Slamon, D. J. et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J. Clin. Oncol. 36, 2465\u20132472 (2018).","journal-title":"J. Clin. Oncol."},{"key":"722_CR19","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1505270","volume":"373","author":"NC Turner","year":"2015","unstructured":"Turner, N. C. et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 373, 209\u2013219 (2015).","journal-title":"N. Engl. J. Med."},{"key":"722_CR20","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","volume":"35","author":"GW Sledge Jr.","year":"2017","unstructured":"Sledge, G. W. Jr. et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with hr+\/her2\u2212 advanced breast cancer who had progressed while receiving endocrine therapy. J. Clin. Oncol. 35, 2875\u20132884 (2017).","journal-title":"J. Clin. Oncol."},{"key":"722_CR21","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMoa1903765","volume":"381","author":"SA Im","year":"2019","unstructured":"Im, S. A. et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N. Engl. J. Med. 381, 307\u2013316 (2019).","journal-title":"N. Engl. J. Med."},{"key":"722_CR22","doi-asserted-by":"publisher","unstructured":"Sledge, G. W. Jr. et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2019.4782 (2019)","DOI":"10.1001\/jamaoncol.2019.4782"},{"key":"722_CR23","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1911149","volume":"382","author":"DJ Slamon","year":"2020","unstructured":"Slamon, D. J. et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N. Engl. J. Med. 382, 514\u2013524 (2020).","journal-title":"N. Engl. J. Med."},{"key":"722_CR24","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1158\/1078-0432.CCR-21-3032","volume":"28","author":"YS Lu","year":"2022","unstructured":"Lu, Y. S. et al. Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+\/HER2\u2212 advanced breast cancer in MONALEESA-7: a phase III randomized clinical trial. Clin. Cancer Res. 28, 851\u2013859 (2022).","journal-title":"Clin. Cancer Res"},{"key":"722_CR25","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1200\/JCO.2016.67.1487","volume":"34","author":"HS Rugo","year":"2016","unstructured":"Rugo, H. S. et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline. J. Clin. Oncol. 34, 3069\u20133103 (2016).","journal-title":"J. Clin. Oncol."},{"key":"722_CR26","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1200\/JCO.18.01624","volume":"37","author":"S Johnston","year":"2019","unstructured":"Johnston, S. et al. Randomized phase II study evaluating palbociclib in addition to letrozole as neoadjuvant therapy in estrogen receptor-positive early breast cancer: PALLET trial. J. Clin. Oncol. 37, 178\u2013189 (2019).","journal-title":"J. Clin. Oncol."},{"key":"722_CR27","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1158\/1078-0432.CCR-14-2258","volume":"21","author":"A DeMichele","year":"2015","unstructured":"DeMichele, A. et al. CDK 4\/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment. Clin. Cancer Res. 21, 995\u20131001 (2015).","journal-title":"Clin. Cancer Res."},{"key":"722_CR28","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1200\/JCO.2016.34.15_suppl.512","volume":"34","author":"NC Turner","year":"2016","unstructured":"Turner, N. C. et al. Efficacy of palbociclib plus fulvestrant (P+F) in patients (pts) with metastatic breast cancer (MBC) and ESR1 mutations (mus) in circulating tumor DNA (ctDNA). J. Clin. Oncol. 34, 512\u2013512 (2016).","journal-title":"J. Clin. Oncol."},{"key":"722_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15916","volume":"8","author":"S Vijayaraghavan","year":"2017","unstructured":"Vijayaraghavan, S. et al. CDK4\/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers. Nat. Commun. 8, 15916 (2017).","journal-title":"Nat. Commun."},{"key":"722_CR30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cell.2007.12.018","volume":"132","author":"B Levine","year":"2008","unstructured":"Levine, B. & Kroemer, G. Autophagy in the pathogenesis of disease. Cell 132, 27\u201342 (2008).","journal-title":"Cell"},{"key":"722_CR31","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nrc3262","volume":"12","author":"E White","year":"2012","unstructured":"White, E. Deconvoluting the context-dependent role for autophagy in cancer. Nat. Rev. Cancer 12, 401\u2013410 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"722_CR32","doi-asserted-by":"publisher","first-page":"856","DOI":"10.15252\/embj.201490784","volume":"34","author":"L Galluzzi","year":"2015","unstructured":"Galluzzi, L. et al. Autophagy in malignant transformation and cancer progression. EMBO J. 34, 856\u2013880 (2015).","journal-title":"EMBO J."},{"key":"722_CR33","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1080\/15548627.2018.1474314","volume":"14","author":"M Mauthe","year":"2018","unstructured":"Mauthe, M. et al. Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy 14, 1435\u20131455 (2018).","journal-title":"Autophagy"},{"key":"722_CR34","doi-asserted-by":"publisher","first-page":"10850","DOI":"10.1074\/jbc.M109.080796","volume":"285","author":"YT Wu","year":"2010","unstructured":"Wu, Y. T. et al. Dual role of 3-methyladenine in modulation of autophagy via different temporal patterns of inhibition on class I and III phosphoinositide 3-kinase. J. Biol. Chem. 285, 10850\u201310861 (2010).","journal-title":"J. Biol. Chem."},{"key":"722_CR35","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1432-1033.1997.0240a.x","volume":"243","author":"EF Blommaart","year":"1997","unstructured":"Blommaart, E. F., Krause, U., Schellens, J. P., Vreeling-Sindelarova, H. & Meijer, A. J. The phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002 inhibit autophagy in isolated rat hepatocytes. Eur. J. Biochem. 243, 240\u2013246 (1997).","journal-title":"Eur. J. Biochem."},{"key":"722_CR36","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.cell.2011.08.037","volume":"147","author":"J Liu","year":"2011","unstructured":"Liu, J. et al. Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13. Cell 147, 223\u2013234 (2011).","journal-title":"Cell"},{"key":"722_CR37","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1158\/2159-8290.CD-17-0741","volume":"7","author":"VW Rebecca","year":"2017","unstructured":"Rebecca, V. W. et al. A unified approach to targeting the lysosome\u2019s degradative and growth signaling roles. Cancer Discov. 7, 1266\u20131283 (2017).","journal-title":"Cancer Discov."},{"key":"722_CR38","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","volume":"16","author":"E Schrezenmeier","year":"2020","unstructured":"Schrezenmeier, E. & Dorner, T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat. Rev. Rheumatol. 16, 155\u2013166 (2020).","journal-title":"Nat. Rev. Rheumatol."},{"key":"722_CR39","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1080\/07853890.2020.1839959","volume":"53","author":"P Bansal","year":"2021","unstructured":"Bansal, P. et al. Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019. Ann. Med. 53, 117\u2013134 (2021).","journal-title":"Ann. Med."},{"key":"722_CR40","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.4161\/auto.29231","volume":"10","author":"D Mahalingam","year":"2014","unstructured":"Mahalingam, D. et al. Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors. Autophagy 10, 1403\u20131414 (2014).","journal-title":"Autophagy"},{"key":"722_CR41","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/0002-9343(83)91265-2","volume":"75","author":"EW McChesney","year":"1983","unstructured":"McChesney, E. W. Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate. Am. J. Med. 75, 11\u201318 (1983).","journal-title":"Am. J. Med."},{"key":"722_CR42","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.4161\/auto.29264","volume":"10","author":"DT Vogl","year":"2014","unstructured":"Vogl, D. T. et al. Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed\/refractory myeloma. Autophagy 10, 1380\u20131390 (2014).","journal-title":"Autophagy"},{"key":"722_CR43","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.4161\/auto.29118","volume":"10","author":"R Rangwala","year":"2014","unstructured":"Rangwala, R. et al. Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy 10, 1369\u20131379 (2014).","journal-title":"Autophagy"},{"key":"722_CR44","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.4161\/auto.29119","volume":"10","author":"R Rangwala","year":"2014","unstructured":"Rangwala, R. et al. Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma. Autophagy 10, 1391\u20131402 (2014).","journal-title":"Autophagy"},{"key":"722_CR45","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1002\/cncr.31335","volume":"124","author":"AV Onorati","year":"2018","unstructured":"Onorati, A. V., Dyczynski, M., Ojha, R. & Amaravadi, R. K. Targeting autophagy in cancer. Cancer 124, 3307\u20133318 (2018).","journal-title":"Cancer"},{"key":"722_CR46","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1200\/JCO.2009.25.6529","volume":"28","author":"ME Hammond","year":"2010","unstructured":"Hammond, M. E. et al. American Society of Clinical Oncology\/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Clin. Oncol. 28, 2784\u20132795 (2010).","journal-title":"J. Clin. Oncol."},{"key":"722_CR47","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","volume":"31","author":"AC Wolff","year":"2013","unstructured":"Wolff, A. C. et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update. J. Clin. Oncol. 31, 3997\u20134013 (2013).","journal-title":"J. Clin. Oncol."},{"key":"722_CR48","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1093\/jnci\/djp079","volume":"101","author":"C Le Tourneau","year":"2009","unstructured":"Le Tourneau, C., Lee, J. J. & Siu, L. L. Dose escalation methods in phase I cancer clinical trials. J. Natl. Cancer Inst. 101, 708\u2013720 (2009).","journal-title":"J. Natl. Cancer Inst."},{"key":"722_CR49","doi-asserted-by":"crossref","unstructured":"Ma, C. X. et al. NeoPalAna: neoadjuvant palbociclib, a cyclin-dependent kinase 4\/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor-positive breast cancer. Clin. Cancer Res. 23, 4055\u20134065 (2017).","DOI":"10.1158\/1078-0432.CCR-16-3206"},{"key":"722_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2023.03.001","volume":"186","author":"L Malorni","year":"2023","unstructured":"Malorni, L. et al. Serum thymidine kinase activity in patients with HR-positive\/HER2\u2212negative advanced breast cancer treated with ribociclib plus letrozole: results from the prospective BioItaLEE trial. Eur. J. Cancer 186, 1\u201311 (2023).","journal-title":"Eur. J. Cancer"},{"key":"722_CR51","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1158\/2767-9764.CRC-23-0257","volume":"3","author":"YC Cheng","year":"2023","unstructured":"Cheng, Y. C. et al. Mathematical modeling identifies optimum palbociclib-fulvestrant dose administration schedules for the treatment of patients with estrogen receptor-positive breast cancer. Cancer Res. Commun. 3, 2331\u20132344 (2023).","journal-title":"Cancer Res. Commun."},{"key":"722_CR52","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"WM Association","year":"2013","unstructured":"Association, W. M. World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310, 2191\u20132194 (2013).","journal-title":"JAMA"},{"key":"722_CR53","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1053\/j.gastro.2014.05.027","volume":"147","author":"A Regev","year":"2014","unstructured":"Regev, A. & Bjornsson, E. S. Drug-induced liver injury: morbidity, mortality, and Hy\u2019s law. Gastroenterology 147, 20\u201324 (2014).","journal-title":"Gastroenterology"},{"key":"722_CR54","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"722_CR55","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1158\/0008-5472.CAN-22-2258","volume":"83","author":"TDT Nguyen","year":"2023","unstructured":"Nguyen, T. D. T. et al. Sequential targeting of retinoblastoma and DNA synthesis pathways is a therapeutic strategy for sarcomas that can be monitored in real time. Cancer Res. 83, 939\u2013955 (2023).","journal-title":"Cancer Res."},{"key":"722_CR56","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1158\/0008-5472.CAN-23-0705","volume":"83","author":"J Navarro-Yepes","year":"2023","unstructured":"Navarro-Yepes, J. et al. Abemaciclib is effective in palbociclib-resistant hormone receptor-positive metastatic breast cancers. Cancer Res. 83, 3264\u20133283 (2023).","journal-title":"Cancer Res."},{"key":"722_CR57","doi-asserted-by":"publisher","first-page":"3873","DOI":"10.1007\/s12035-022-02825-3","volume":"59","author":"K Mondal","year":"2022","unstructured":"Mondal, K. et al. Hydroxychloroquine causes early inner retinal toxicity and affects autophagosome-lysosomal pathway and sphingolipid metabolism in the retina. Mol. Neurobiol. 59, 3873\u20133887 (2022).","journal-title":"Mol. Neurobiol."},{"key":"722_CR58","unstructured":"Krishnamurthy, J. et al. In: Cancer Research. (Amer Assoc Cancer Research 615 Chestnut St, 17th Floor, Philadelphia, Pa \u2026)."},{"key":"722_CR59","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/nrm2233","volume":"8","author":"J Campisi","year":"2007","unstructured":"Campisi, J. & d\u2019Adda di Fagagna, F. Cellular senescence: when bad things happen to good cells. Nat. Rev. Mol. Cell Biol. 8, 729\u2013740 (2007).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"722_CR60","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1101\/gad.519709","volume":"23","author":"AR Young","year":"2009","unstructured":"Young, A. R. et al. Autophagy mediates the mitotic senescence transition. Genes Dev. 23, 798\u2013803 (2009).","journal-title":"Genes Dev."},{"key":"722_CR61","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1158\/2159-8290.CD-19-0292","volume":"9","author":"RK Amaravadi","year":"2019","unstructured":"Amaravadi, R. K., Kimmelman, A. C. & Debnath, J. Targeting autophagy in cancer: recent advances and future directions. Cancer Discov. 9, 1167\u20131181 (2019).","journal-title":"Cancer Discov."},{"key":"722_CR62","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/s41568-022-00450-9","volume":"22","author":"L Wang","year":"2022","unstructured":"Wang, L., Lankhorst, L. & Bernards, R. Exploiting senescence for the treatment of cancer. Nat. Rev. Cancer 22, 340\u2013355 (2022).","journal-title":"Nat. Rev. Cancer"},{"key":"722_CR63","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/nature12437","volume":"501","author":"JR Dorr","year":"2013","unstructured":"Dorr, J. R. et al. Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. Nature 501, 421\u2013425 (2013).","journal-title":"Nature"},{"key":"722_CR64","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1172\/JCI64098","volume":"123","author":"T Tchkonia","year":"2013","unstructured":"Tchkonia, T., Zhu, Y., van Deursen, J., Campisi, J. & Kirkland, J. L. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J. Clin. Invest. 123, 966\u2013972 (2013).","journal-title":"J. Clin. Invest."},{"key":"722_CR65","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.4161\/auto.20958","volume":"8","author":"RK Amaravadi","year":"2012","unstructured":"Amaravadi, R. K. & Winkler, J. D. Lys05: a new lysosomal autophagy inhibitor. Autophagy 8, 1383\u20131384 (2012).","journal-title":"Autophagy"},{"key":"722_CR66","doi-asserted-by":"publisher","first-page":"8253","DOI":"10.1073\/pnas.1118193109","volume":"109","author":"Q McAfee","year":"2012","unstructured":"McAfee, Q. et al. Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency. Proc. Natl. Acad. Sci. USA 109, 8253\u20138258 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"722_CR67","doi-asserted-by":"crossref","unstructured":"Cechakova, L. et al. A potent autophagy inhibitor (Lys05) enhances the impact of ionizing radiation on human lung cancer cells H1299. Int. J. Mol. Sci. 20, 5881 (2019)","DOI":"10.3390\/ijms20235881"},{"key":"722_CR68","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1172\/JCI70454","volume":"124","author":"XH Ma","year":"2014","unstructured":"Ma, X. H. et al. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. J. Clin. Invest. 124, 1406\u20131417 (2014).","journal-title":"J. Clin. Invest."},{"key":"722_CR69","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1042\/BCJ20210284","volume":"478","author":"D Ahwazi","year":"2021","unstructured":"Ahwazi, D. et al. Investigation of the specificity and mechanism of action of the ULK1\/AMPK inhibitor SBI-0206965. Biochem. J. 478, 2977\u20132997 (2021).","journal-title":"Biochem. J."},{"key":"722_CR70","doi-asserted-by":"publisher","unstructured":"Ghazi, P. C. et al. Inhibition of ULK1\/2 and KRAS (G12C) controls tumor growth in preclinical models of lung cancer. bioRxiv. https:\/\/doi.org\/10.1101\/2024.02.06.579200 (2024)","DOI":"10.1101\/2024.02.06.579200"}],"container-title":["npj Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41523-025-00722-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-025-00722-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-025-00722-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T11:24:37Z","timestamp":1737890677000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41523-025-00722-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,26]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["722"],"URL":"https:\/\/doi.org\/10.1038\/s41523-025-00722-1","relation":{},"ISSN":["2374-4677"],"issn-type":[{"value":"2374-4677","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,26]]},"assertion":[{"value":"14 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.T.: Quantum Leap Healthcare. K.K.H.: Armada Health, AstraZeneca, Cairn Surgical, Eli Lilly & Co, Lumicell. K.K.: Apeiron, BluePrint, REPARE, Schrodinger and Novartis. The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7"}}